Edesa Biotech Highlighting 278-Patient Mortality Reductions at May 2026 Respiratory Summit
Edesa Biotech’s Phase 3 study of paridiprubart in ARDS patients covered 278 participants, showing statistically significant mortality reductions versus placebo across both invasive and non-invasive ventilation groups. CEO Par Nijhawan will deliver the inaugural oral presentation on May 15 at the ATS 2026 Respiratory Innovation Summit, highlighting these positive data.
1. Phase 3 Results Demonstrate Mortality Benefit
The Phase 3 trial of paridiprubart enrolled 278 ARDS patients—104 on invasive mechanical ventilation and 174 non-IMV—showing statistically significant reductions in mortality versus placebo across both cohorts.
2. Inaugural Oral Presentation at Respiratory Innovation Summit
CEO Par Nijhawan will deliver the opening oral showcase on May 15 at the 2026 Respiratory Innovation Summit, with principal investigator Ted Steiner presenting full Phase 3 data on May 20 during the ATS International Conference.
3. Anti-TLR4 Host-Directed Therapeutic
Paridiprubart is a first-in-class anti-TLR4 antibody designed to modulate the immune response in ARDS, offering a new host-directed therapeutic approach stockpiled for public health emergencies and acute respiratory failure.
4. Broader Pipeline and Funding Support
Edesa’s pipeline also includes EB06 for vitiligo and EB01 for allergic contact dermatitis, while paridiprubart has received two Canadian government awards and is part of a U.S. government-funded platform study for ARDS.